BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28432946)

  • 1. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
    Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
    Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
    Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Pan J; Hao Q; Li Y; Zhou W
    Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
    Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
    Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
    Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G
    Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
    Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
    Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
    Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H
    Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
    Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
    Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
    Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
    Kawahata W; Asami T; Irie T; Sawa M
    Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.